Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity.

[1]  N. Papadopoulos,et al.  PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze , 2018, Nature Communications.

[2]  J. Nosek,et al.  Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine , 2017, Front. Microbiol..

[3]  M. Boukhvalova,et al.  Immunization with Live Human Rhinovirus (HRV) 16 Induces Protection in Cotton Rats against HRV14 Infection , 2017, Front. Microbiol..

[4]  N. Papadopoulos,et al.  Promising approaches for the treatment and prevention of viral respiratory illnesses , 2017, Journal of Allergy and Clinical Immunology.

[5]  M. Rossmann,et al.  Antibody-induced uncoating of human rhinovirus B14 , 2017, Proceedings of the National Academy of Sciences.

[6]  C. Yip,et al.  Rhinovirus - From bench to bedside. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[7]  J. Tregoning,et al.  Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre , 2017, Front. Microbiol..

[8]  J. Andersen,et al.  Antibody-antigen kinetics constrain intracellular humoral immunity , 2016, Scientific Reports.

[9]  A. Pomés,et al.  Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans , 2016, The Journal of Immunology.

[10]  J. Gern,et al.  A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques , 2016, Nature Communications.

[11]  W. Thomas,et al.  Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C , 2016, Journal of Virology.

[12]  J. Gern,et al.  Rhinoviruses and Their Receptors: Implications for Allergic Disease , 2016, Current Allergy and Asthma Reports.

[13]  J. Andersen,et al.  TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity , 2015, Immunological reviews.

[14]  L. James,et al.  TRIM21 Promotes cGAS and RIG-I Sensing of Viral Genomes during Infection by Antibody-Opsonized Virus , 2015, PLoS pathogens.

[15]  S. Johnston,et al.  Challenges in developing a cross-serotype rhinovirus vaccine. , 2015, Current opinion in virology.

[16]  M. Boukhvalova,et al.  Prophylactic antibody treatment and intramuscular immunization reduce infectious human rhinovirus 16 load in the lower respiratory tract of challenged cotton rats , 2014, Trials in Vaccinology.

[17]  B. Guy,et al.  Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Protein , 2013, PLoS pathogens.

[18]  S. Johnston,et al.  Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. , 2012, Antiviral research.

[19]  R. Valenta,et al.  Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation , 2010, European Respiratory Journal.

[20]  T. Smith,et al.  Antibodies to the Buried N Terminus of Rhinovirus VP4 Exhibit Cross-Serotypic Neutralization , 2009, Journal of Virology.

[21]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[22]  B. Chain,et al.  Characterization of the T cell response to human rhinovirus in children: implications for understanding the immunopathology of the common cold. , 1997, The Journal of infectious diseases.

[23]  R. Vrtis,et al.  Rhinovirus-specific T cells recognize both shared and serotype-restricted viral epitopes. , 1997, The Journal of infectious diseases.

[24]  M. Rossmann,et al.  The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle. , 1997, Structure.

[25]  W. Doyle,et al.  Prechallenge Antibodies: Moderators of Infection Rate, Signs, and Symptoms in Adults Experimentally Challenged With Rhinovirus Type 39 , 1996, The Laryngoscope.

[26]  Timothy S. Baker,et al.  Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon , 1996, Nature.

[27]  D. Blaas,et al.  Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. , 1994, The EMBO journal.

[28]  T. Baker,et al.  Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Betzel,et al.  Three‐dimensional structure of the Fab fragment of a neutralizing antibody to human rhinovirus serotype 2 , 1992, Protein science : a publication of the Protein Society.

[30]  D. Tyrrell,et al.  The specificity of antibodies induced by infection with rhinovirus type 2 , 1992, Journal of medical virology.

[31]  J. Vadolas,et al.  Neutralization epitopes of human rhinovirus type 2. , 1990, The Journal of general virology.

[32]  D. Tyrrell,et al.  The time course of the humoral immune response to rhinovirus infection , 1989, Epidemiology and Infection.

[33]  J. Tomassini,et al.  Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments , 1989, Journal of virology.

[34]  G. Werner,et al.  Different rhinovirus serotypes neutralized by antipeptide antibodies , 1987, Nature.

[35]  B. Clarke,et al.  A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. , 1987, The Journal of general virology.

[36]  W. Sommergruber,et al.  A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2. , 1987, The Journal of general virology.

[37]  B. Sherry,et al.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14 , 1986, Journal of virology.

[38]  John E. Johnson,et al.  Structure of a human common cold virus and functional relationship to other picornaviruses , 1985, Nature.

[39]  J. Fox.  Is a rhinovirus vaccine possible? , 1976, American journal of epidemiology.

[40]  R. M. Conant,et al.  Human responses to two decavalent rhinovirus vaccines. , 1975, The Journal of infectious diseases.

[41]  R. Douglas,et al.  Parenteral Inactivated Rhinovirus Vaccine: Minimal Protective Effect 1 , 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[42]  J. C. Perkins,et al.  Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. , 1972, Journal of immunology.

[43]  J. C. Perkins,et al.  Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. , 1969, American journal of epidemiology.

[44]  R. M. Conant,et al.  Rhinoviruses: basis for a numbering system. II. Serologic characterization of prototype strains. , 1968, Journal of immunology.

[45]  R. M. Conant,et al.  Rhinoviruses: basis for a numbering system. 1. HeLa cells for propagationand serologic procedures. , 1968, Journal of immunology.

[46]  Mitchison Da.  CHEMOTHERAPY OF TUBERCULOSIS: A BACTERIOLOGIST'S VIEWPOINT. , 1965 .

[47]  D. Mitchison.  Prevention of Colds by Vaccination against a Rhinovirus , 1965, British medical journal.

[48]  D. Tyrrell,et al.  Some Attempts to Produce an Experimental Vaccine with Rhinoviruses , 1963, British medical journal.